Sale!

Phospholipase A2 Receptor Antibody PLA2R Qualitative Test Cost

Original price was: 1,140 د.إ.Current price is: 1,030 د.إ.

-10%

The Phospholipase A2 Receptor Antibody (PLA2R) Qualitative Test is a specialized diagnostic assessment designed to detect the presence of antibodies against the PLA2R in the blood. This test plays a crucial role in diagnosing and managing autoimmune conditions, particularly primary membranous nephropathy (PMN), a kidney disorder characterized by the thickening of the capillary walls in the glomeruli due to immune complex deposition. The presence of PLA2R antibodies is strongly associated with PMN, making this test an essential tool for nephrologists and other healthcare professionals in both the diagnosis and monitoring of the disease progression or response to therapy.

The test is conducted at DNA Labs UAE, a state-of-the-art facility known for its advanced diagnostic services and commitment to precision medicine. The cost of the Phospholipase A2 Receptor Antibody (PLA2R) Qualitative Test at DNA Labs UAE is 1030 AED. This investment provides patients and their healthcare providers with critical information that can guide treatment decisions and potentially improve patient outcomes by allowing for early and targeted intervention.

Description

PHOSPHOLIPASE A2 RECEPTOR ANTIBODY PLA2R QUALITATIVE Test

Test Name: PHOSPHOLIPASE A2 RECEPTOR ANTIBODY PLA2R QUALITATIVE Test

Components: 2 mL (1 mL min.) serum from 1 SST

Price: 1030.0 AED

Sample Condition: Ship refrigerated or frozen. Overnight fasting is preferred.

Report Delivery: SampleTue / Fri by 9 am; Report Same day

Method: IFA

Test Type: Disorders of Kidney

Doctor: Nephrologist

Test Department: IMMUNOPATHOLOGY

Pre Test Information: Overnight fasting is preferred.

Test Details:

The Phospholipase A2 Receptor Antibody (PLA2R) Qualitative Test is a diagnostic test used to detect the presence of antibodies against the phospholipase A2 receptor in the blood. This test is primarily used in the diagnosis and monitoring of autoimmune diseases, specifically primary membranous nephropathy (PMN).

PMN is a kidney disease characterized by the thickening of the glomerular basement membrane due to the deposition of immune complexes. The phospholipase A2 receptor is the main target antigen in approximately 70-80% of cases of PMN. Detecting antibodies against this receptor can help confirm the diagnosis of PMN and distinguish it from secondary causes of membranous nephropathy.

The PLA2R Qualitative Test is performed using a blood sample. The sample is tested for the presence of antibodies against the phospholipase A2 receptor using various techniques such as enzyme-linked immunosorbent assay (ELISA) or immunofluorescence. A positive result indicates the presence of antibodies against the phospholipase A2 receptor, suggesting a diagnosis of primary membranous nephropathy. However, it is important to note that a negative result does not rule out PMN, as there are cases where antibodies against the receptor are not detected.

The PLA2R Qualitative Test is a valuable tool in the diagnosis and management of primary membranous nephropathy, helping healthcare providers make informed treatment decisions and monitor disease progression.

Test Name	PHOSPHOLIPASE A2 RECEPTOR ANTIBODY PLA2R QUALITATIVE Test
Components
Price	1030.0 AED
Sample Condition	2 mL (1 mL min.) serum from 1 SST. Ship refrigerated or frozen. Overnight fasting is preferred.
Report Delivery	SampleTue / Fri by 9 am; Report Same day
Method	IFA
Test type	Disorders of Kidney
Doctor	Nephrologist
Test Department:	IMMUNOPATHOLOGY
Pre Test Information	Overnight fasting is preferred.
Test Details	The Phospholipase A2 Receptor Antibody (PLA2R) Qualitative Test is a diagnostic test used to detect the presence of antibodies against the phospholipase A2 receptor in the blood. This test is primarily used in the diagnosis and monitoring of autoimmune diseases, specifically primary membranous nephropathy (PMN). PMN is a kidney disease characterized by the thickening of the glomerular basement membrane due to the deposition of immune complexes. The phospholipase A2 receptor is the main target antigen in approximately 70-80% of cases of PMN. Detecting antibodies against this receptor can help confirm the diagnosis of PMN and distinguish it from secondary causes of membranous nephropathy. The PLA2R Qualitative Test is performed using a blood sample. The sample is tested for the presence of antibodies against the phospholipase A2 receptor using various techniques such as enzyme-linked immunosorbent assay (ELISA) or immunofluorescence. A positive result indicates the presence of antibodies against the phospholipase A2 receptor, suggesting a diagnosis of primary membranous nephropathy. However, it is important to note that a negative result does not rule out PMN, as there are cases where antibodies against the receptor are not detected. The PLA2R Qualitative Test is a valuable tool in the diagnosis and management of primary membranous nephropathy, helping healthcare providers make informed treatment decisions and monitor disease progression.